Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE:QGEN) launched QIA Agent, an AI-powered digital assistant that supports experiment planning, product discovery and workflow guidance through a single conversational interface on www.qiagen.com.
The platform links natural-language queries to QIAGEN products, protocols, technical documentation and ordering tools, leveraging over 260,000 registered My QIAGEN users. It is globally available for research use only, not for diagnostic applications.
QIAGEN (NYSE:QGEN) is integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform into QIAGEN Digital Insights’ curated biomedical knowledge bases to support AI-driven drug discovery.
The collaboration applies graph-based AI to biomedical knowledge graphs to aid target identification, biomarker discovery and hypothesis generation, with initial pilot programs for select pharma and biotech partners.
QIAGEN (NYSE:QGEN) will propose several measures at its June 24, 2026 Annual General Meeting in Venlo. Key items include appointing co-founder Dr. Metin Colpan as Honorary Chairman, continued Supervisory Board renewal, a 40% dividend increase to $0.35 per share, and expanded share repurchase authorizations.
The company seeks approval for open-market buybacks of up to 10% of share capital plus a new $200 million synthetic share repurchase. CEO Thierry Bernard and CFO Roland Sackers are proposed for re-election to the Managing Board while a new CEO is expected in the second half of 2026.
QIAGEN (NYSE:QGEN) plans a fully automated QuantiFERON Sample to Insight workflow and an AI-enabled risk stratification tool, both targeted for late 2027. The workflow integrates QuantiFERON, Diasorin LIAISON systems and an Inpeco automation track. QIAGEN cites a ~75M annual latent TB test market growing ~4–5%/yr and reports >160M QuantiFERON tests performed.
QIAGEN (NYSE: QGEN) reported Q1 2026 net sales of $492 million (+2% reported, -1% CER) and diluted EPS of $0.33; adjusted diluted EPS was $0.54 CER, meeting the outlook. Adjusted operating margin was 27.4%. Sample technologies, QIAcuity and QDI grew; QuantiFERON fell on weaker immigration testing. Full‑year 2026 guidance reconfirmed at ~1–2% CER sales growth and adjusted diluted EPS of at least $2.43 CER.
QIAGEN (NYSE: QGEN) reported preliminary Q1 2026 results: net sales $492M (+2% reported, -1% CER) and adjusted diluted EPS $0.54 (in line with outlook). Sample technologies grew 9% CER; QuantiFERON declined 5% CER.
Full-year 2026 net sales outlook revised to about 1–2% CER growth (prior: at least 5% CER); adjusted EPS now at least $2.43 CER (prior: $2.50). Q2 sales forecast ~-2% CER. Conference call April 28; full results May 6, 2026.
QIAGEN (NYSE: QGEN) will showcase its Sample to Insight oncology solutions at AACR Annual Meeting 2026, highlighting automated sample prep, single-cell Evercode kits, new QIAseq research panels, the QIAsymphony Connect automation platform, QIAsprint Connect throughput system, and the QIAGEN Discovery Platform for AI-grounded drug discovery support.
Demonstrations run April 17–22 at Booth #3547 and include the Evercode WT FFPE kit now shipping after early access and QIAsymphony Connect built on over 3,300 placements.
QIAGEN (NYSE: QGEN) launched the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel on April 14, 2026, expanding its QIAstat-Dx syndromic testing portfolio into bloodstream infection diagnostics. The panel identifies 20 gram-positive and fungal pathogens plus 10 antimicrobial resistance markers from positive blood cultures or colonies in about one hour.
QIAGEN said the system integrates sample prep, molecular testing and analysis, is available in >100 countries, and had >5,200 instruments placed worldwide as of end-2025. Additional panels targeting gram-negative pathogens are in development.
QIAGEN (NYSE: QGEN) filed its Form 20-F annual report for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission on March 20, 2026. The filing includes the audited consolidated financial statements for 2025.
According to the company, the report is available on QIAGEN's website and printed copies will be provided to shareholders free of charge upon request via the contact form or email to ir@qiagen.com.
QIAGEN (NYSE: QGEN) highlighted new clinical and health economic data supporting QuantiFERON-TB Gold Plus (QFT-Plus) for TB infection detection, especially in immunocompromised and high-risk groups. A Thailand study found QFT-Plus cut modeled lifetime progression risk to active TB by 41% vs tuberculin skin testing and lowered lifetime healthcare costs.
QIAGEN noted > 2,500 published studies and > 125 million QuantiFERON tests used globally. A CPD-accredited QuantiFERON World TB Day online program is scheduled for March 24, 2026.